Flagship and Lean are looking to combine Lean’s platform and ecosystem with Flagship’s expertise in building and launching biopharmaceutical companies in Saudi Arabia.
Saudi Arabia’s sovereign wealth fund-backed Lean will provide its data infrastructure in an attempt to strengthen the nation’s artificial intelligence, analytics, and digital health.
The agreement isn’t the first collaboration between Flagship and an entity in Saudi Arabia. In 2025, the country’s biggest medical research institute, King Abdullah International Medical Research Center, signed a deal to test Flagship companies’ candidates in early clinical trials.
The deal this week is all about Flagship’s reach and creating biotech ecosystems with the talent, data, and regulatory framework required for the highest quality science, said Flagship Senior Partner Junaid Bajwa.
“What we do today is just an extension of reaching for science capital; there is amazing science capital out there that we want to get a hold of,” Bajwa said. “Who in the world has amazing data for different populations that have been forgotten that we can prosecute with science? Who has temporal data in an appropriately consented, ethically created manner with whom we could work? Lean” is an example of that.
Flagship’s companies are creating dozens of drug programs annually, and the Lean partnership unlocks unique, genetically-based data sets from individuals that may be underrepresented in clinical trials and patient populations in the U.S.
“There is a certain capability in a centralized data source in this population to be able to target better, and to better select patients for clinical trials,” Flagship Vice President of Global Initiatives, Strategy and Operations Yiqun Bai, told Fierce Biotech. Measurable change to specific drug programs coming out of the Flagship ecosystem would be considered a success.
As part of the country’s Vision 2030 plan, Saudi Arabia is in the midst of building out its biotech ecosystem to become a global hub by 2040. The National Biotechnology Strategy was launched by Crown Prince Mohammed bin Salman to support the development of Saudi Arabia’s pace in four directions: vaccines, biomanufacturing and localization, genomics, and plant optimization. The plan calls for economic diversification while promoting the development of biotech manufacturing and discovery.
As the Kingdom’s national leader in health transformation, Lean is dedicated to supporting innovation to enhance health outcomes and further science progress, Mohanned Alrasheed, chief executive officer at Lean Business Services, said in the release. We are committed to contributing to Saudi Arabia’s life sciences landscape and its Vision 2030 goal for the Kingdom to be a world leader in health innovation, in partnership with Flagship Pioneering.
Bajwa termed the Kingdom as a ‘wonderful partner’ as Flagship aims to emulate expansions in London and Singapore in recent years.
“They’re creating this whole ecosystem today, and they’re letting us create that ecosystem with them.” “They’re giving their citizens access to new treatments that they would not have had access to otherwise, and they’re creating the clinical trials system and pushing the limits of what they can do.”
Flagship announced a new research partnership with a business backed by Saudi Arabia’s sovereign wealth fund during BIO 2026, marking another step toward expanding international collaboration in biotechnology. The agreement highlights Flagship’s commitment to accelerating scientific innovation while strengthening global research partnerships.
Flagship Expands Global Research Collaboration
A major collaboration announced during BIO 2026 highlights the growing importance of international partnerships in advancing biotechnology innovation. The agreement brings together a business backed by Saudi Arabia’s sovereign wealth fund and one of the world’s leading life sciences innovation firms to accelerate research, foster scientific discovery, and support the development of next-generation healthcare solutions. The partnership reflects a broader trend of combining global investment with cutting-edge research to address complex medical challenges.
A Shared Vision for Innovation
The collaboration is built on a shared commitment to advancing biotechnology through long-term investment in scientific research. Both organizations plan to leverage their complementary strengths to identify promising technologies, support early-stage innovation, and create opportunities for groundbreaking discoveries. The partnership aims to establish a strong foundation for future research initiatives across multiple therapeutic areas.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
